US company Kite Pharma (Nasdaq: KITE) has confirmed the death of a patient in one of its Phase I/II studies, but this was not related to the drug being tested.
The patient was in the study of CAR-T therapy KTE-C19 for refractory aggressive non-Hodgkin’s lymphoma in patients who have failed prior chemo treatments and has a poor prognosis, although the company said the death was unrelated to the therapy.
The US Food and Drug Administration did not ask Kite to pause patient enrolment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze